FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
165th Meeting of the Vaccines and Related Biological Products Advisory Committee
Silver Spring, MD
March 5, 2021
AGENDA

Topic: The Committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2021 – 2022 influenza season.

Time	Presentation/Presenter
9:00am – 9:10am	**Opening Remarks: Call to Order, Introduction of Committee** Hana El Sahly, M.D., Chair, VRBPAC
9:10am – 9:30am	**Administrative Announcements, Roll Call, Introduction of Committee, Conflict of Interest Statement** Kathleen Hayes, M.P.H. Designated Federal Officer, VRBPAC CBER, FDA
9:30am – 9:45am	**Influenza Virus Vaccine Strain Selection 2021-2022 Northern Hemisphere** Jerry Weir, Ph.D. Director Division of Viral Products (DVP) Office of Vaccines Research and Review (OVRR) CBER, FDA Q &A: 5 min
9:45am – 10:10am	**U.S. Influenza Surveillance** Lisa Grohskopf, M.D., M.P.H. CAPT USPHS Associate Chief for Policy & Liaison Activities, Epidemiology & Prevention Branch, Influenza Division Centers for Disease Control and Prevention (CDC) Q &A: 5 min
10:10am – 11:20am	**Global Influenza Virus Surveillance and Characterization** David Wentworth, Ph.D. Branch Chief Influenza Division Virology, Surveillance, and Diagnostic Branch Centers for Disease Control and Prevention (CDC) Q &A: 10 min

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
165th Meeting of the Vaccines and Related Biological Products Advisory Committee
Silver Spring, MD
March 5, 2021
AGENDA

11:20am – 11:30am	**BREAK**
11:30am – 11:55am	**DoD Influenza Surveillance and Mid-Season Vaccine Effectiveness** LTC Kevin Taylor, M.D., MTM&H Focus Area Chief Global Emerging Infections Surveillance Branch Armed Forces Health Surveillance Division Public Health Division - DHA Kathleen Creppage, DrPh., M.P.H Senior Epidemiologist Armed Forces Health Surveillance Division Global Emerging Infections Surveillance Branch Q &A: 5 min
11:55am – 12:20pm	**Candidate Vaccine Strains & Potency Reagents** Manju Joshi, Ph.D. Lead Biologist Division of Biological Standards & Quality Office of Compliance and Biologics Quality CBER/FDA Q &A: 5 min
12:20pm – 12:45pm	**Comments from Manufacturer Representative** Lauren Parker, Ph.D. AstraZeneca Q &A: 5 min
12:45pm – 1:30pm	**Lunch** (45 min.)
1:30pm – 2:30pm	**Open Public Hearing** (60 min.)
2:30pm – 3:30pm	**Committee Discussion, Recommendations, and Vote**
3:30 pm	**Adjourn Meeting**